← Back to Clinical Trials
Recruiting NCT07009093

NCT07009093 Utility of a Mobile Application for Young Women With Breast Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07009093
Status Recruiting
Phase
Sponsor Wake Forest University Health Sciences
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2026-04
Primary Completion 2027-07

Trial Parameters

Condition Breast Cancer
Sponsor Wake Forest University Health Sciences
Study Type INTERVENTIONAL
Phase N/A
Enrollment 120
Sex FEMALE
Min Age 18 Years
Max Age 45 Years
Start Date 2026-04
Completion 2027-07
Interventions
Mighty Pro Application

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.

Eligibility Criteria

Inclusion Criteria: * Ability to understand and willingness to sign an IRB-approved informed consent * Age ≥ 18 and ≤ 45 years at the time of consent * Female * Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC) * Histological confirmation of any type and stage (0-IV) of breast cancer * Screening (baseline) NCCN Distress Thermometer score ≥ 4 * Access to a mobile device for trial purposes and an active email address * Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only. * As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study Exclusion Criteria: \- None

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology